country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-P99335

Copy Link Print Information

Vunakizumab

(Synonyms: Anti-Human IL17A Recombinant Antibody; SHR-1314)

Customer Review

Based on 1 Customer Validation

Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a recombinant human IgGκ monoclonal antibody and an Interleukin-17A (IL-17A) inhibitor. Vunakizumab binds to IL-17A to inhibit downstream cytokines and block inflammatory signaling. Vunakizumab can be used for the research of chronic plaque psoriasis and ankylosing spondylitis.

For research use only. We do not sell to patients.

Purity: 95.00%
CAS No.: 1792181-33-9
Molecular Weight:146.38 kDa

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Vunakizumab Chemical Structure

CAS No.: 1792181-33-9

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Isotype
- Recommend Isotype Controls
- Species Reactivity
- IC₅₀ & Target
- In Vitro
- In Vivo
- Clinical Trial
- Gene ID
- Accession
- Conjugated
- Reconsititution
- Format
- Application
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Isotype

Human IgG1 kappa

Recommend Isotype Controls

Human IgG1 kappa, Isotype Control

Species Reactivity

Human

IC₅₀ & Target^[1]

IL-17A

All Interleukin Related Isoforms :

In Vitro

Vunakizumab inhibits IL-17A-dependent fibrosis and adipogenesis in human CD34⁺ orbital fibroblasts^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Vunakizumab efficiently antagonizes lL-17 and improves psoriasis in mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Gene ID

3605 [NCBI]

Accession

Q16552

Conjugated

Unconjugated

Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.

Format

Human IgG1 kappa

Application

ELISA, FACS, Functional assay

Chemical Information

CAS No. 1792181-33-9
Appearance Liquid
Molecular Weight 146.38 kDa
Color Colorless to light yellow
SMILES

[Vunakizumab]
Synonyms

Anti-Human IL17A Recombinant Antibody; SHR-1314
Shipping

Shipping with dry ice.
Formulation

Please refer to the lot-specific COA for specific buffer information.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (256 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Inhibitory Antibodies User Guide (603 KB)

References

[1]. Liu SH, et al. Recent Advances of Second-Line Targeted Biopharmaceutical Therapies in Thyroid Associated Ophthalmopathy. Adv. Therap. 2024 Jul 05;7(9):2400137.

[2]. Zhang C, et al. A multicenter, randomized, double-blinded, placebo-controlled, dose-ranging study evaluating the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis. J Am Acad Dermatol.

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote

Amount: USD 0.00

Biological Activity
- Description
- Isotype
- Recommend Isotype Controls
- Species Reactivity
- IC₅₀ & Target
- In Vitro
- In Vivo
- Clinical Trial
- Gene ID
- Accession
- Conjugated
- Reconsititution
- Format
- Application
Chemical Information
Purity & Documentation
References

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Vunakizumab

Cell-ATP Viability Detection Kit

Protein A Agarose

HOLO Human Interleukin-2 (IL-2) Detection Kit

Bradford Protein Assay Kit

PBS Buffer (1×)

DPBS Buffer (1×)

Cytotoxicity LDH Assay Kit

Antibody Inhibitor Library

All Interleukin Related Isoforms

Biological Activity

Chemical Information

Purity & Documentation

References

Calculators

Help & FAQs

Vunakizumab Related Classifications

HY-P99335 Related Classifications